Repare Therapeutics  logo
Repare Therapeutics RPTX
$ 1.83 -0.54%

Quarterly report 2025-Q2
added 08-08-2025

report update icon

Repare Therapeutics Cash Flow 2011-2025 | RPTX

Annual Cash Flow Repare Therapeutics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-76.4 M -127 M 322 K -85.8 M -6.08 M -18.4 M - - - - - - - -

Depreciation & Amortization

1.92 M 1.95 M 1.98 M 1.47 M 897 K 605 K - - - - - - - -

Accounts Payables

3.62 M 2.4 M 461 K 2.3 M 2.25 M - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Repare Therapeutics

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- -29.1 M - - - 11.9 M - - - -31.8 M - 30 M - -30 M - -65.1 M - -14.2 M - 6.86 M 27 M -9.72 M - -9.08 M -3.23 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

- 1.19 M - - - 501 K - - - 441 K - 1.52 M - 516 K - 1.1 M - 322 K - 610 K 403 K 196 K - 416 K 262 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

4.01 M 2.28 M 3.62 M 10.7 M 7.18 M 6.82 M 2.4 M 5.44 M 4.89 M 3.62 M 461 K 9.34 M - 1.55 M 2.3 M 1.86 M 3.3 M 3.35 M 2.25 M 2.25 M 2.25 M 2.25 M 2.13 M 2.13 M 2.13 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Repare Therapeutics , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Graybug Vision Graybug Vision
GRAY
$ 0.44 -11.23 % $ 9.65 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
$ 11.3 -10.17 % $ 12.2 K -
Galera Therapeutics Galera Therapeutics
GRTX
$ 0.14 -32.59 % $ 7.61 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
$ 4.37 -1.58 % $ 28.1 M chinaChina
Axon Enterprise Axon Enterprise
AXON
$ 723.51 -1.19 % $ 54.8 B usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
$ 0.43 -16.75 % $ 25.8 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
$ 0.27 -29.58 % $ 126 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
$ 184.71 0.49 % $ 251 B cayman-islandsCayman-islands
Heron Therapeutics Heron Therapeutics
HRTX
$ 1.2 3.02 % $ 183 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
$ 1.47 -5.16 % $ 5.39 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
$ 4.93 1.02 % $ 90.8 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
$ 0.29 -18.52 % $ 27.3 M britainBritain
Advaxis Advaxis
ADXS
$ 0.31 -9.65 % $ 45.9 M usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
$ 6.2 - $ 154 M usaUSA
Zymeworks Zymeworks
ZYME
$ 6.42 - $ 404 M canadaCanada
Aeterna Zentaris Aeterna Zentaris
AEZS
$ 5.72 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
$ 10.5 - $ 231 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
$ 2.58 -4.8 % $ 255 M usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
$ 0.56 7.23 % $ 2.72 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
$ 0.5 - $ 7.46 M israelIsrael
Kiromic BioPharma Kiromic BioPharma
KRBP
$ 3.15 6.61 % $ 3.08 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
$ 44.15 -0.23 % $ 916 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
$ 0.32 - $ 23.9 M usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
$ 0.29 -3.69 % $ 12.4 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
$ 2.19 - $ 105 M usaUSA
Humanigen Humanigen
HGEN
$ 0.04 -81.12 % $ 4.28 M usaUSA
Aptinyx Aptinyx
APTX
$ 0.06 -39.0 % $ 4.57 M usaUSA
Tyme Technologies Tyme Technologies
TYME
$ 0.31 8.07 % $ 54 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
$ 2.64 -0.75 % $ 18.7 M danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
$ 0.39 - $ 26.5 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
$ 0.47 - $ 12.5 M belgiumBelgium
Brickell Biotech Brickell Biotech
BBI
$ 2.11 -5.38 % $ 6.06 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
$ 0.05 -15.0 % $ 3.04 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
$ 0.06 -55.98 % $ 2.15 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
$ 8.37 - $ 401 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
$ 3.17 1.93 % $ 17.4 M usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
$ 49.14 -0.62 % $ 421 B danmarkDanmark
Calithera Biosciences Calithera Biosciences
CALA
$ 0.37 -10.95 % $ 876 K usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
$ 20.01 - $ 958 M usaUSA
Oncolytics Biotech Oncolytics Biotech
ONCY
$ 1.09 -8.58 % $ 115 M canadaCanada
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
$ 49.55 -6.81 % $ 3.04 B usaUSA
ORIC Pharmaceuticals ORIC Pharmaceuticals
ORIC
$ 12.52 -4.86 % $ 873 M usaUSA
Sierra Oncology Sierra Oncology
SRRA
$ 54.89 -0.05 % $ 1.34 B canadaCanada
Regulus Therapeutics Regulus Therapeutics
RGLS
$ 8.16 - $ 155 M usaUSA
Precigen Precigen
PGEN
$ 4.17 0.72 % $ 1.02 B usaUSA